» Articles » PMID: 22274890

Effects of Oestrogen on MicroRNA Expression in Hormone-responsive Breast Cancer Cells

Abstract

Oestrogen receptor alpha (ERα) is a ligand-dependent transcription factor that mediates oestrogen effects in hormone-responsive cells. Following oestrogenic activation, ERα directly regulates the transcription of target genes via DNA binding. MicroRNAs (miRNAs) represent a class of small noncoding RNAs that function as negative regulators of protein-coding gene expression. They are found aberrantly expressed or mutated in cancer, suggesting their crucial role as either oncogenes or tumour suppressor genes. Here, we analysed changes in miRNA expression in response to oestrogen in hormone-responsive breast cancer MCF-7 and ZR-75.1 cells by microarray-mediated expression profiling. This led to the identification of 172 miRNAs up- or down-regulated by ERα in response to 17β-oestradiol, of which 52 are similarly regulated by the hormone in the two cell models investigated. To identify mechanisms by which ERα exerts its effects on oestrogen-responsive miRNA genes, the oestrogen-dependent miRNA expression profiles were integrated with global in vivo ERα binding site mapping in the genome by ChIP-Seq. In addition, data from miRNA and messenger RNA (mRNA) expression profiles obtained under identical experimental conditions were compared to identify relevant miRNA target transcripts. Results show that miRNAs modulated by ERα represent a novel genomic pathway to impact oestrogen-dependent processes that affect hormone-responsive breast cancer cell behaviour. MiRNome analysis in tumour tissues from breast cancer patients confirmed a strong association between expression of these small RNAs and clinical outcome of the disease, although this appears to involve only marginally the oestrogen-regulated miRNAs identified in this study.

Citing Articles

Inhibition of miRNA associated with a disease-specific signature and secreted via extracellular vesicles of systemic lupus erythematosus patients suppresses target organ inflammation in a humanized mouse model.

Young N, Schwarz E, Zeno B, Bruckner S, Mesa R, Jablonski K Front Immunol. 2024; 14:1090177.

PMID: 38939646 PMC: 11208704. DOI: 10.3389/fimmu.2023.1090177.


Hormonal regulation of miRNA during mammary gland development.

Confuorti C, Jaramillo M, Plante I Biol Open. 2024; 13(6).

PMID: 38712984 PMC: 11190577. DOI: 10.1242/bio.060308.


Human Breast Milk microRNAs, Potential Players in the Regulation of Nervous System.

Freiria-Martinez L, Iglesias-Martinez-Almeida M, Rodriguez-Jamardo C, Rivera-Baltanas T, Comis-Tuche M, Rodrigues-Amorim D Nutrients. 2023; 15(14).

PMID: 37513702 PMC: 10384760. DOI: 10.3390/nu15143284.


Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies.

Ozyurt R, Ozpolat B Cancers (Basel). 2022; 14(21).

PMID: 36358625 PMC: 9655708. DOI: 10.3390/cancers14215206.


Novel estrogen-responsive genes (ERGs) for the evaluation of estrogenic activity.

Nishi K, Fu W, Kiyama R PLoS One. 2022; 17(8):e0273164.

PMID: 35976950 PMC: 9385026. DOI: 10.1371/journal.pone.0273164.


References
1.
Hall J, Couse J, Korach K . The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem. 2001; 276(40):36869-72. DOI: 10.1074/jbc.R100029200. View

2.
Kim V, Han J, Siomi M . Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10(2):126-39. DOI: 10.1038/nrm2632. View

3.
Zhao Y, Srivastava D . A developmental view of microRNA function. Trends Biochem Sci. 2007; 32(4):189-97. DOI: 10.1016/j.tibs.2007.02.006. View

4.
Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G . Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem. 2000; 275(8):5379-87. DOI: 10.1074/jbc.275.8.5379. View

5.
McDonnell D, Norris J . Connections and regulation of the human estrogen receptor. Science. 2002; 296(5573):1642-4. DOI: 10.1126/science.1071884. View